Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Repligen Corporation - Common Stock (NQ: RGEN )

141.40 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 82
Open 141.40
Bid (Size) 103.10 (1)
Ask (Size) 149.00 (6)
Prev. Close 141.40
Today's Range 141.40 - 141.40
52wk Range 102.97 - 182.52
Shares Outstanding 55,679,964
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Repligen (RGEN): Buy, Sell, or Hold Post Q4 Earnings?
Repligen trades at $120.32 per share and has moved almost in lockstep with the market over the last six months. The stock has lost 10.5% while the S&P 500 is down 7.7%. This might have investors... 
Via StockStory
Topics Stocks
Exposures US Equities
Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how IQVIA (NYSE:IQV) and the rest... 
Via StockStory

Performance

YTD
-1.15%
-1.15%
1 Month
-2.58%
-2.58%
3 Month
-15.25%
-15.25%
6 Month
+2.85%
+2.85%
1 Year
-17.45%
-17.45%

More News

Read More
Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers
Via StockStory
Demystifying Repligen: Insights From 6 Analyst Reviews
Via Benzinga
The Analyst Verdict: Repligen In The Eyes Of 4 Experts
Via Benzinga
Earnings Scheduled For February 20, 2025
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Evaluating Repligen: Insights From 6 Financial Analysts
Via Benzinga
Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks
Via StockStory
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
Via StockStory
3 Small-Cap Stocks Skating on Thin Ice
Via StockStory
These Analysts Revise Their Forecasts On Repligen Following Q2 Results
Via Benzinga
908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth
Via Benzinga
Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook
Via Benzinga
Repligen's Q4 Slightly Tops Expectations
Via The Motley Fool
Repligen (NASDAQ:RGEN) Posts Q4 Sales In Line With Estimates
Via StockStory
Exposures COVID-19
Earnings To Watch: Repligen (RGEN) Reports Q4 Results Tomorrow
Via StockStory
3 Healthcare Stocks Skating on Thin Ice
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth
Via Benzinga
Topics Earnings
Exposures Financial
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Wall Street Ticks Up As Consumer Sentiment Improves; Gold Hits Record Highs, Boosting Mining Stocks: What's Driving Markets Friday?
Via Benzinga
Shake Shack And Lumen Tech Are Among Top 7 Mid Cap Stocks With Max Gains Last Week (July 28-August 3): Are The Others In Your Portfolio?
Via Benzinga
Here's Why Shares in This Hot Healthcare Stock Surged This Week
Via The Motley Fool
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.